Medical Editor: John P. Cunha, DO, FACOEP
Myxredlin (insulin human in sodium chloride injection) is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. Common side effects of Myxredlin include:
The dose of Myxredlin is individualized based on metabolic needs, blood glucose monitoring results, and glycemic control goal. Myxredlin may interact with antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs, sulfonamide antibiotics, atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, alcohol, beta-blockers, lithium salts, and pentamidine, clonidine, guanethidine, and reserpine. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Myxredlin; it is not expected to harm a fetus. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy. Myxredlin passes into breast milk. Consult your doctor before breastfeeding.
Our Myxredlin (insulin human in sodium chloride injection), for Intravenous Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The following adverse reactions are also discussed elsewhere in the labeling:
- Hypoglycemia [see WARNINGS AND PRECAUTIONS]
- Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS]
- Hypokalemia [see WARNINGS AND PRECAUTIONS]
Adverse Reactions From Clinical Studies Or Postmarketing Reports
The following additional adverse reactions have been identified during clinical studies or from postmarketing reports with use of insulin human injection. Because some of these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure.
Adverse Reactions Associated With Insulin Initiation And Glucose Control Intensification
Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy. Over the long-term, improved glycemic control decreases the risk of diabetic retinopathy and neuropathy.
Severe, life-threatening, generalized allergy, including anaphylaxis.
Hypoglycemia is the most commonly observed adverse reaction with MYXREDLIN.
MYXREDLIN can cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia.
Insulins, including MYXREDLIN, may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.
Weight gain can occur with insulin therapies, including MYXREDLIN, and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.
As with all therapeutic peptides, insulin administration may cause anti-insulin antibodies to form. Increases in titers of anti-insulin antibodies that react with human insulin have been observed in patients treated with subcutaneous insulin human injection.
Read the entire FDA prescribing information for Myxredlin (Insulin Human in Sodium Chloride Injection)